Ultimovacs Receives Notice of Allowance for U.S. Patent on

  • Extends protection of UV1 vaccine-checkpoint inhibitor combinations until at least 2037
  • Covers UV1 with CTLA-4, PD-1 or PD-L1 checkpoint inhibitors

Oslo, 22 April 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical leader in immunostimulatory cancer vaccines, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding its application US Patent 16/306,352 on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to issuance formalities, it is expected that a patent will be issued with a validity period until at least June 2037. Ultimovacs has similar patent applications pending in other jurisdictions around the world, including Europe, Japan, Canada and Australia.

The scope of the patent, once issued, will cover cancer treatments that include the UV1 peptide vaccine in combination with an anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody. The primary patents on many of the current CTLA-4 and PD-1/PD-L1 checkpoint inhibitors are at risk of expiring in the next few years.

“We are delighted that Ultimovacs’ innovative contributions to combination cancer immunotherapies have been validated by the USPTO,” said Carlos de Sousa, CEO of Ultimovacs. “The company’s universal UV1 cancer vaccine is being evaluated in combination with checkpoint inhibitors in five phase 2 trials for various cancers. The authorized claims will cover these combination treatments in these and other cancer indications and extend the exclusive use of the vaccine in combination with these checkpoint inhibitors until at least 2037. »


About Ultimovacs
Ultimovacs develops immunostimulating vaccines to treat a wide range of cancers. UV1, Ultimovacs’ lead universal cancer vaccine candidate, targets human telomerase (hTERT), present in 85-90% of cancers at all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 directs CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With an extensive phase II program, Ultimovacs aims to clinically demonstrate the impact of UV1 in several types of cancer in combination with other immunotherapies. Ultimovacs’ second technology approach, based on the proprietary Tetanus Epitope Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.

For more information, please visit www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: [email protected]
Telephone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: [email protected]
Telephone: +47 906 86815

Mary-Ann Chang, LifeSci Advisors
Email: [email protected]
Telephone: +44 7483 284 853

This information is considered inside information under the EU Market Abuse Regulation and is subject to disclosure requirements under section 5-12 of the Norwegian Securities Act.

This stock announcement was published by Joachim Midtun, Finance Manager at Ultimovacs ASA, the 22 April, 2022 to 8:00 HEC


Comments are closed.